SCHEMBL3924760

SCHEMBL3924760

CC(C)CNc1nccc(N(C)c2cc(-c3ccccc3)c3ncn(C)c3c2)n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 11/20 0.43
▸ ESR1 P03372 1/20 0.37
▸ DPP4 P27487 1/20 0.35
▸ KDR P35968 2/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ EPHB4 P54760 1/20 0.35
▸ CCNE1 P24864 3/20 0.34
▸ CDK2 P24941 3/20 0.34
▸ CCNT1 O60563 1/20 0.34
▸ CDK9 P50750 1/20 0.34
▸ CDK5 Q00535 1/20 0.34
▸ CDK5R1 Q15078 1/20 0.34
▸ CCNE2 O96020 2/20 0.34
▸ PRMT5 O14744 1/20 0.34
▸ WDR77 Q9BQA1 1/20 0.34
▸ CDC7 O00311 1/20 0.33
▸ CCNA2 P20248 1/20 0.33
▸ CCNA1 P78396 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3935077 0.85 MAP3K5 (0.41) DPP4KDRFGFR1EPHB4CCNE1
SCHEMBL3924645 0.83 CCNE2 (0.45) HRH4KDRFGFR1EPHB4CCNE1
SCHEMBL3927808 0.83 NPC1 (0.36) HRH4ESR1DPP4KDRFGFR1
SCHEMBL3924707 0.82 MKNK1 (0.45) HRH4KDRFGFR1CCNE1CDK2
SCHEMBL3922932 0.81 KDR (0.39) KDRFGFR1EPHB4CDK2CDK5
SCHEMBL3926763 0.80 DPP4 (0.36) DPP4KDRFGFR1EPHB4CDK2
SCHEMBL3923646 0.79 VCP (0.35) HRH4DPP4KDRFGFR1EPHB4
SCHEMBL3927416 0.79 MAPK14 (0.36) DPP4KDRFGFR1EPHB4
SCHEMBL3927419 0.79 KDR (0.33) DPP4KDRFGFR1EPHB4CDK2
SCHEMBL3933169 0.79 MAPK14 (0.36) DPP4KDRFGFR1EPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2041118-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen, Inc (US) 2009-04-01 — — EP claimed
WO-2007114827-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2007-10-11 — — WO claimed
US-20060247263-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2006-11-02 — — US claimed
EP-2041118-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen, Inc (US) 2009-04-01 — — EP disclosed
WO-2007114827-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2007-10-11 — — WO disclosed
WO-2007114827-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2007-10-11 — — WO disclosed
US-20060247263-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2006-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247263-A1 Substituted heterocyclic compounds and methods of use MAPT, IAPP, MYLK2 HRH4 24/4885ESR1 1963/4885DPP4 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback